IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Forte Capital LLC ADV

Forte Capital LLC ADV cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,650 shares of the medical research company’s stock after selling 1,920 shares during the period. IQVIA makes up approximately 1.2% of Forte Capital LLC ADV’s holdings, making the stock its 26th largest holding. Forte Capital LLC ADV’s holdings in IQVIA were worth $8,711,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in IQV. AMF Tjanstepension AB purchased a new position in IQVIA in the third quarter valued at about $148,096,000. Eagle Asset Management Inc. purchased a new stake in shares of IQVIA in the third quarter valued at $102,982,000. iA Global Asset Management Inc. boosted its stake in shares of IQVIA by 1,225.3% during the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after purchasing an additional 296,105 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in IQVIA by 2,765.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock worth $53,381,000 after acquiring an additional 261,848 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of IQVIA by 33.4% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock worth $240,505,000 after purchasing an additional 260,271 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the topic of a number of research analyst reports. Truist Financial decreased their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Barclays lifted their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Evercore ISI dropped their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $257.57.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 over the last three months. 1.60% of the stock is owned by insiders.

IQVIA Stock Up 0.6 %

Shares of NYSE IQV traded up $1.23 during midday trading on Friday, reaching $223.37. 1,052,929 shares of the company’s stock were exchanged, compared to its average volume of 831,136. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market capitalization of $40.54 billion, a PE ratio of 30.52, a price-to-earnings-growth ratio of 2.16 and a beta of 1.52. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.86 and a current ratio of 0.88. The business’s fifty day moving average price is $244.08 and its two-hundred day moving average price is $224.01.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same period in the previous year, the company earned $2.54 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. Analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.